SOTYLIZE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOTYLIZE (SOTYLIZE).
Selective beta-1 adrenergic receptor antagonist; also exhibits class III antiarrhythmic activity (potassium channel blockade), prolonging cardiac repolarization and refractory periods.
| Metabolism | Primarily hepatic via CYP2D6 (minor contribution); renal excretion of unchanged drug (50-70%) and metabolites. |
| Excretion | Primarily renal excretion of unchanged drug; 85-90% eliminated unchanged in urine, with the remainder via feces (<5%) and minimal biliary excretion. |
| Half-life | Terminal elimination half-life is 12-16 hours in patients with normal renal function; can extend up to 30-40 hours in renal impairment, requiring dose adjustment. |
| Protein binding | Minimal, approximately 0% (sotalol is not significantly bound to plasma proteins). |
| Volume of Distribution | Approximately 1.2-2.4 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Oral: >90% (virtually complete) with first-pass metabolism <5%, negligible liver metabolism. |
| Onset of Action | Oral: 1-2 hours; intravenous: immediate (within 5 minutes). |
| Duration of Action | Oral: 12-24 hours; intravenous: 6-12 hours. Duration is prolonged in renal impairment and may last >24 hours. |
Initial: 80 mg orally twice daily. May increase every 2-3 days in 40-80 mg increments up to 240-320 mg/day. Maximum: 320 mg/day in divided doses.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-60 mL/min: reduce dose by 25%; GFR 10-29 mL/min: reduce dose by 50%; GFR <10 mL/min: use with caution, reduce dose by 75%. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50%; Child-Pugh Class C: contraindicated. |
| Pediatric use | Not FDA-approved for pediatric patients; off-label use: 2-4 mg/kg/day orally divided twice daily, titrate cautiously. |
| Geriatric use | Start at lowest dose (40 mg twice daily) with gradual titration; monitor renal function and heart rate; increased risk of bradycardia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SOTYLIZE (SOTYLIZE).
| Breastfeeding | Sotalol is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.1–0.2. Relative infant dose is about 2–4% of maternal weight-adjusted dose. Considered cautionary: monitor infant for bradycardia, hypotension, and hypoglycemia. Avoid in breastfeeding if possible, especially in neonates with impaired renal function. |
| Teratogenic Risk | SOTYLIZE (sotalol) is a Class III antiarrhythmic. First trimester: Risk based on animal data (fetal toxicity at maternally toxic doses); human data limited, but sotalol crosses placenta. Second/third trimesters: Risk of fetal bradycardia, reduced uterine blood flow, and hypoglycemia. May cause fetal growth restriction. Human studies show no major teratogenicity in first trimester, but cases of neonatal bradycardia and hypotonia. Risk of arrhythmia in mother may warrant use. |
■ FDA Black Box Warning
May worsen ventricular arrhythmias (proarrhythmic effect); avoid in patients with sinus bradycardia, heart block > 1st degree, cardiogenic shock, or decompensated heart failure. Requires gradual withdrawal to prevent exacerbation of ischemia/infarction.
| Serious Effects |
Sinus bradycardia, sick sinus syndrome, AV block (2nd/3rd degree), cardiogenic shock, decompensated heart failure, bronchial asthma, hypersensitivity to sotalol or any component.
| Precautions | Bradycardia, heart failure exacerbation, bronchospasm in asthmatics, masked hypoglycemia/hyperthyroidism symptoms, risk of anaphylaxis, hypotension, QT prolongation (dose-dependent), electrolyte disturbances, renal impairment dose adjustment. |
Loading safety data…
| Fetal Monitoring | Maternal: ECG for QTc prolongation, heart rate, blood pressure. Fetal: Doppler ultrasound for heart rate, growth scans (2nd/3rd trimester) for intrauterine growth restriction. Neonatal: Monitor for respiratory depression, bradycardia, hypoglycemia, and arrhythmias for 48–72 hours postpartum. |
| Fertility Effects | No human studies on fertility. In animal studies, no impairment of male or female fertility at clinically relevant doses. Beta-blockers may rarely cause erectile dysfunction in men. Sotalol is not known to affect ovulation or sperm parameters. |